How Sex Hormone-Binding Globulin Changes With Age
Sex hormone-binding globulin (SHBG) is a liver-derived glycoprotein that binds androgens and estrogens with high affinity. This page summarises what the available clinical evidence shows about how SHBG changes with age,
What is sex hormone-binding globulin?
Sex hormone-binding globulin (SHBG) is a glycoprotein synthesised primarily in the liver. It binds testosterone and estradiol with high affinity and regulates their bioavailability. The evidence block for this page does not provide sequence, formula, or molecular weight identifiers for SHBG; those details are therefore not stated here.
The work described in the evidence centres on hepatic SHBG synthesis and its suppression by hyperinsulinaemia, a pathway relevant to insulin resistance and androgen excess.
Research Studies
SHBG and hyperinsulinaemia in polycystic ovary syndrome
In polycystic ovary syndrome (PCOS), insulin resistance is described as playing a central role in pathophysiology. Hyperinsulinaemia can enhance ovarian androgen production and reduce hepatic SHBG synthesis, thereby aggravating hyperandrogenism and reproductive abnormalities [1]. This describes a mechanism by which SHBG levels may be lowered in the context of insulin resistance, but the evidence block does not provide age-stratified SHBG values.
SHBG and DPP-4 inhibition in PCOS
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis. Emerging evidence suggests that DPP-4 inhibition may also influence body weight, androgen excess, inflammation, and other parameters [1]. The evidence block does not report direct measurements of SHBG in response to vildagliptin, nor does it provide age-related changes.
SHBG and hepatic steatosis in adolescent girls with PCOS
A prospective observational study (COMPASS-pedPCOS) will evaluate whether PCOS contributes to hepatic steatosis in adolescent girls independently of adiposity. The study will enrol 150 girls aged 10–18 years into three groups: girls with PCOS and obesity, age- and BMI-matched girls with obesity but without PCOS, and healthy normal-weight girls. Each participant will undergo anthropometry, clinical and biochemical phenotyping, transient elastography with controlled attenuation parameter and two-dimensional shear wave elastography, and a single venous blood sample [2]. The evidence block does not state that SHBG will be measured or reported in this study.
SHBG and age: what the evidence shows
The evidence block does not contain data on how SHBG changes with age. The studies described focus on PCOS, insulin resistance, and hepatic steatosis in specific populations (adults in [1], adolescent girls in [2]). No age-stratified SHBG values are provided.
SHBG and insulin resistance: mechanism
Hyperinsulinaemia can reduce hepatic SHBG synthesis [1]. This provides a mechanistic link between insulin resistance and lower SHBG, but the evidence block does not quantify this relationship or describe how it varies with age.
SHBG and androgen excess in PCOS
Reduced hepatic SHBG synthesis, driven by hyperinsulinaemia, can aggravate hyperandrogenism [1]. This is a described pathway, not a measured outcome in the evidence block.
SHBG in adolescent girls: study population
The COMPASS-pedPCOS study population is girls aged 10–18 years [2]. This is the only age range specified in the evidence block. No SHBG data are reported for this population.
SHBG and DPP-4 inhibition: indirect evidence
DPP-4 inhibition may influence androgen excess and inflammation [1]. Any effect on SHBG would be indirect and is not reported in the evidence block.
Summary of evidence gaps
The evidence block does not provide data on how SHBG changes with age. It describes mechanisms by which SHBG synthesis may be reduced (hyperinsulinaemia) and study populations (adults with PCOS, adolescent girls with and without PCOS), but no age-related SHBG measurements are given.
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.